MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 557.4 USD | +0.90% |
|
+1.06% | +20.39% |
| 05-17 | JPMorgan Adjusts McKesson Price Target to $656 From $589 | MT |
| 05-16 | McKesson Seeks Acquisitions | CI |
| Sales 2025 * | 358B 28,145B | Sales 2026 * | 386B 30,332B | Capitalization | 72.45B 5,694B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.72B 292B | Net income 2026 * | 3.9B 306B | EV / Sales 2025 * | 0.2 x |
| Net cash position 2025 * | 320M 25.12B | Net cash position 2026 * | 2.66B 209B | EV / Sales 2026 * | 0.18 x |
| P/E ratio 2025 * |
19.1
x | P/E ratio 2026 * |
17.8
x | Employees | 48,000 |
| Yield 2025 * |
0.48% | Yield 2026 * |
0.53% | Free-Float | 46.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
More news
| 1 day | +0.90% | ||
| 1 week | +1.06% | ||
| Current month | +3.75% | ||
| 1 month | +5.70% | ||
| 3 months | +9.23% | ||
| 6 months | +21.85% | ||
| Current year | +20.39% |
1 week
548.81
566.16
1 month
518.27566.16
Current year
462.70566.16
1 year
373.28566.16
3 years
184.43566.16
5 years
112.60566.16
10 years
106.11566.16
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 31/12/11 |
| Director of Finance/CFO | 55 | 26/01/18 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 19/10/14 |
Webster Dunbar
BRD | Director/Board Member | 62 | 31/03/22 |
| Director/Board Member | 66 | 12/01/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.43% | 9 M€ | 0.00% | ||
| 2.31% | 1,085 M€ | +8.34% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/05/24 | 557.4 | +0.90% | 743,931 |
| 21/05/24 | 552.4 | -2.06% | 876,849 |
| 20/05/24 | 564 | -0.09% | 576,473 |
| 17/05/24 | 564.5 | +1.58% | 575,688 |
| 16/05/24 | 555.8 | +0.76% | 758,618 |
Delayed Quote Nyse, May 22, 2024 at 09:00 pm
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
02/06/2024
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
557.4
USD
Average target price
584.1
USD
Spread / Average Target
+4.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.39% | 72.45B | |
| -4.44% | 23.46B | |
| +4.89% | 8.59B | |
| +7.83% | 8.35B | |
| -21.35% | 7.88B | |
| +14.90% | 5.21B | |
| +10.84% | 4.09B | |
| -1.97% | 4.11B | |
| -0.69% | 3.87B | |
| +20.72% | 3.6B |
- Stock Market
- Equities
- MCK Stock
